Under the Agreement, MGC Pharma will provide THC with an immediate supplementary source of medicinal cannabis products, which will be packaged and made available to patients under the Canndeo brand.
THC expects to launch these products in Australia and New Zealand through Q1 2020.
THC chief executive officer Ken Charteris said: “Our agreement with MGC Pharma provides THC Global with an immediate extension of our Canndeo branded medicinal cannabis product range, as well as a pathway for further collaboration with MGC Pharma taking advantage of THC Globals Southport Facility – the largest pharmaceutical bio-floral extraction facility in the Southern Hemisphere – and MGC Pharmas Maltese facility.
"We look forward to taking advantage of our market development activities in Australia, New Zealand, Canada, and Asia as we launch this new product range over the course of the next two months.”
Scaling up supply
The agreement also provides for MGC Pharma and THC to collaborate on the future supply of active pharmaceutical ingredients (API) extracts as well as other finished product, including from THCs Southport Facility.
Accessing an immediate supplementary source of medicinal cannabis products, enables THC to scale up its supply to patients quicker, and offer patients a broader initial product range under the Canndeo brand.
The agreement with MGC Pharma also provides THC with access to tetrahydrocannabinol (THC) containing formulatioRead More – Source